Biomarker Menu
Biomarker Menu

Explore Our Biomarker Menu

Including 400+ Biomarker Offerings for a Range of Disease States

Return to Biomarker Menu

Biomarker: IL-16 (serum)

Search for Biomarkers

Analyte:

IL-16 (serum)

Platform:

Matrix:

Human Serum

Status:

Experienced Running

Biological or Clinical Significance:

Pro-interleukin-16 is a protein that in humans is encoded by the IL16 gene. Interleukin 16 (IL-16) is a cytokine that is released by a variety of cells (including lymphocytes and some epithelial cells) that has been characterized as a chemoattractant for certain immune cells expressing the cell surface molecule CD4. IL-16 was originally described as a factor that could attract activated T cells in humans, it was previously called lymphocyte chemoattractant factor (LCF). Since then, this interleukin has been shown to recruit and activate many other cells expressing the CD4 molecule, including monocytes, eosinophils, and dendritic cells. The structure of IL-16 was determined following its cloning in 1994. This cytokine is produced as a precursor peptide (pro-IL-16) that requires processing by an enzyme called caspase-3 to become active. CD4 is the cell signaling receptor for mature IL-16.

References:

Speak to a Scientist

















What would you like to discuss?

With whom will we be speaking?






I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.

Yes I confirm that I am over the age of 16 and I consent to communications from BioAgilytix.


biomarker services

Services

See how our premier bioanalytical services support all phases of biomarker, immunogenicity, PK, and cell-based assay studies.

Explore our services

case studies

Case Studies

Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.

Read our case studies